Best's Market Segment Report: Reinsurers' Disciplined Capital Deployment and Underwriting Remain Key Foundations
The Best's Market Segment Report, 'Reinsurers' Disciplined Capital Deployment and Underwriting Remain Key Foundations,' starts off AM Best's look at the global reinsurance industry ahead of the Rendez-Vous de Septembre in Monte Carlo. Other reports, including AM Best's ranking of top global reinsurance groups and in-depth looks at the insurance-linked securities, Lloyd's, life/annuity, health and regional reinsurance markets, will be available during August and September.
According to this report, the shift since the January 2023 renewal in how risk is priced, shared and retained across the reinsurance industry has carried forward and translated into a second-straight year of solid results in 2024. The European 'Big Four' reinsurers posted a discounted combined ratio of 86.4% under IFRS 17; the discounting on average lowers the combined ratio by approximately eight percentage points. The U.S. and Bermuda composite reported an undiscounted combined ratio of 89.5% under U.S. GAAP. These results confirm that underwriting profitability has not only rebounded but is being sustained in the current reinsurance cycle.
'Reinsurers' risk-adjusted capitalization levels remain robust, reflecting retained earnings and disciplined capital management, and the strong underwriting profitability is being augmented by a surge in investment income given elevated interest rates,' said Michael Lagomarsino, senior director, AM Best. 'The absence of material new global reinsurance entrants also is ensuring that structural market discipline is maintained, distinguishing the current environment from previous market cycles.'
According to the report, most global reinsurers have maintained their strong performance through the first half of 2025, despite global weather-related insured losses that will likely top USD 100 billion. These losses are primarily driven by the California wildfires, which many reinsurers are marking in the range of USD 30-50 billion. 'Assuming no further material weather events in the second half of 2025, the combination of disciplined underwriting, rate adequacy and robust investment income should deliver full-year operating results exceeding the cost of capital,' said Dan Hofmeister, associate director, AM Best.
Global reinsurers also face headwinds other than climate change, including social inflation, growing geopolitical tensions and trade disputes, and these challenges underscore the importance of the market's improved structural foundations and explain why AM Best's outlook, though positive, remains closely scrutinized.
'The question now facing the industry is whether the improvements in terms and conditions represent a durable shift,' said Steven Chirico, director, AM Best. 'The lessons of past cycles suggest caution, but reinsurer sentiment has ensured tighter exposure management and market disciple in the current cycle.'
To access the full copy of this market segment report, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=356685.
For global reinsurance reports ahead of Rendez-Vous de Septembre, as well as video coverage of the event, please visit AM Best's Reinsurance Information center.
Lastly, AM Best will host its annual reinsurance market briefing at Rendez-Vous de Septembre on Sept. 7, 2025, at 10:15 a.m. (CEST) in Monte Carlo. For more information, please visit the event website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Business Wire
2 hours ago
- Business Wire
Statement from CUPE on Air Canada's Request for Binding Arbitration
TORONTO--(BUSINESS WIRE)--The Air Canada Component of CUPE has respectfully urged Employment Minister Patty Hajdu not to intervene pursuant to section 107 of the Canada Labour Code thereby permitting collective bargaining to continue and allowing the parties to negotiate a resolution. The integrity of the collective bargaining process depends on allowing the parties to reach a resolution through free and fair negotiations, without undue interference. Rather than continuing to negotiate in good faith, Air Canada appears to have anticipated government intervention and has opted to suspend meaningful discussions, contrary to its legal obligation to bargain in good faith. On August 11, 2025, the Union submitted a revised wage proposal, which included the withdrawal of its long-standing position seeking the same wage adjustment previously provided by Air Canada to its pilots. Despite this significant concession, Air Canada declined to meaningfully engage with the proposal and did not present a counter-proposal. On August 12, 2025, the Union made additional and substantial modifications to its wage position. The Union did not receive a response to its proposals, instead, it learned for the first time, when meeting with Minister Hajdu on August 12, 2025, that it had been rejected. On August 12, 2025, Air Canada unilaterally declared an impasse and withdrew from the bargaining table. It has not returned. On August 12, 2025, unbeknownst to the Union, the Company made an extraordinary and premature request to the Minister seeking the application of section 107 to prevent a strike or lockout. It is clear from Air Canada's submissions to the Minister that it had planned to withdraw from bargaining and ask the Minister to interfere with the bargaining process. Early on August 13, 2025, given Air Canada's refusal to bargain, the Union issued notice of its intent to commence a legal strike beginning Saturday, August 16, 2025. Within minutes, Air Canada served a lockout notice. The Union submits that the appropriate course of action is for Air Canada to return to the table and resume good faith bargaining. Accordingly, Air Canada's request for ministerial intervention under section 107 should be firmly rejected. The mere prospect of ministerial intervention has had a chilling effect on Air Canada's obligation to bargain in good faith. Air Canada's request for intervention should be denied. Such a decision would reaffirm the principles of free collective bargaining and compel Air Canada to return to the bargaining table – where it ought to be – and engage meaningfully in negotiations, where it is likely that the Parties may be able to reach an agreement.
Business Wire
2 hours ago
- Business Wire
CIBL, Inc. Reports Second Quarter Operating Results
RENO, Nev.--(BUSINESS WIRE)--CIBL, Inc. ('CIBL' or the 'Company'; OTC Pink ®: CIBY), a holding company with interests in broadband operations in New Hampshire, reported its financial results for the quarter ended June 30, 2025. Revenues increased 4.1% to $529,000 in the second quarter of 2025 from $508,000 in the second quarter 2024 Earnings per share were $5.60 per share in the second quarter of 2025 compared to a loss per share of $5.22 in the second quarter 2024 Cash and investments, net of zero debt, were $20,452 as of June 30, 2025 Christopher Nossokoff joined CIBL as a mergers and acquisitions advisor to provide and accelerate our interest in non-organic growth Results from Operations Three Months Ended June 30, 2025 Revenues increased 4.1% to $529,000 in the second quarter 2025 from $508,000 in the second quarter 2024 due to increased service revenues from broadband, end-user terminals and voice over internet protocol. EBITDA from operations 1 decreased 21.3% to $118,000 in the second quarter 2025 compared to $150,000 in the second quarter 2024 due to less capitalized labor for plant under construction and switch replacements. Six Months Ended June 30, 2025 Revenues increased 7.9% to $1,053,000 for the six months ended June 30, 2025 from $976,000 for the six months ended June 30, 2024 due to new services, one-time equipment revenues and system upgrades. EBITDA from operations 1 decreased 16.8% to $242,000 for the six months ended June 30, 2025 from $291,000 for the six months ended June 30, 2024 due to the increase in revenues discussed above partially offset by less capitalized labor for plant under construction and switch replacements. _______________ 1 A reconciliation of non-GAAP financial measures to the most comparable GAAP measure is provided at the end of this press release. Expand Other Highlights Capital expenditures were $45,000 and $164,000 for the six months ended June 30, 2025, and 2024, respectively. During the six months ended June 30, 2025, the Company acquired 725 of its shares at an average price of $1,690 per share. As of June 30, 2025, CIBL has 11,541 shares outstanding. Since its spin-off from LICT Corporation in 2007, CIBL has repurchased 15,325 of its shares for $21.8 million, or an average price of $1,420 per share. CIBL's Board of Directors continues to evaluate a broad range of strategic alternatives for the company to create shareholder value. About CIBL, Inc. CIBL is a holding company with interests in broadband operations. CIBL's operations consist of Bretton Woods Telephone Company and World Surfer, Inc. providers of broadband and communication services in Northern New Hampshire. CIBL is listed on OTC Pink® under the symbol CIBY and information can be obtained on our website: Cautionary Note Concerning Forward-Looking Statements To the extent this release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, it should be recognized that such information is based upon assumptions, projections and forecasts, including without limitation business conditions and financial markets, and the cautionary statements set forth in documents filed by CIBL on its website, Thus, such information is subject to uncertainties, risks and inaccuracies, which could be material, and there can be no assurance that such information will prove to be accurate. CIBL Inc. and Subsidiaries Attachment B Consolidated Balance Sheets (Unaudited) (USD in thousands, except share data) December 31, 2024 (Audited) June 30, 2024 Assets Current assets Cash and cash equivalents $ 1,594 $ 2,341 $ 1,348 Investments in United States Treasury Bills 16,550 16,598 18,841 Investment in available for sale equity securities 44 294 279 Investment in equity method limited partnership 1,706 1,645 1,595 Accounts receivable 253 284 221 Prepaid expenses 94 192 71 Materials and supplies 59 59 59 Income taxes receivable 37 - 43 Total current assets 20,337 21,413 22,457 Telecommunications, property, plant and equipment, net 907 958 771 Goodwill 337 337 337 Other intangibles, net 25 30 35 Other investments 1,708 1,636 700 Deferred income taxes 34 39 50 Other assets 59 59 71 Total assets $ 23,407 $ 24,472 $ 24,421 Liabilities Current liabilities Income taxes payable $ -- $ 14 $ -- Trade accounts payable and accrued expenses 142 138 124 Accrued liabilities 353 284 381 Total current liabilities 495 436 505 Other liabilities 46 46 59 Total liabilities 541 482 564 Equity Common stock, par value $.01, 30,000 shares authorized; 26,865, 26,865 and 26,415 issued; and 11,541, 12,266 and 12,399 outstanding -- -- -- Contributed capital 7,112 7,112 6,212 Retained earnings 37,545 37,416 37,147 Treasury stock, 15,325; 14,600; and 14,017 shares at cost (21,791 ) (20,538 ) (19,502 ) Total equity 22,866 23,990 23,857 Total liabilities and equity $ 23,407 $ 24,472 $ 24,421 Expand CIBL Inc. and Subsidiaries Attachment C EBTIDA Reconciliation (Unaudited) (USD in thousands, except share data) The following table is a reconciliation of EBITDA from operations to Net income (loss): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) $ 65 $ (65 ) $ 129 $ (126 ) Adjustments: Interest income (185 ) (266 ) (377 ) (521 ) Income tax expense (benefit) 20 (31 ) 34 (46 ) Depreciation and amortization 52 34 100 65 Total adjustments (113 ) (263 ) (243 ) (502 ) EBITDA (48 ) (328 ) (114 ) (628 ) Corporate office expenses 273 280 509 523 Equity in earnings of affiliated companies (107 ) 127 (133 ) 283 Unrealized and realized losses on available for sale equity securities - 71 (20 ) 113 EBITDA from operations $ 118 $ 150 $ 242 $ 291 Expand
